Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance.
Saved in:
| Title: | Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance. |
|---|---|
| Authors: | Dolan M; Department of Experimental Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States of America., Mastri M; Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States of America., Tracz A; Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States of America., Christensen JG; Mirati Therapeutics, San Diego, California, United States of America., Chatta G; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States of America., Ebos JML; Department of Experimental Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States of America.; Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States of America.; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States of America. |
| Source: | PloS one [PLoS One] 2019 Aug 01; Vol. 14 (8), pp. e0220101. Date of Electronic Publication: 2019 Aug 01 (Print Publication: 2019). |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
